CRON Cronos Group
- 2.650
- -0.030-1.12%
- 2.650
- 0.0000.00%
Cronos Group News
B of A Securities: Maintaining the Cronos Group (CRON.US) rating, adjusted from below the market to below the market rating, and adjusted the target price from $2.00 to $2.50.
Cronos Group Analyst Ratings
B of A Securities Maintains Underperform on Cronos Group, Raises Price Target to $2.5
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)
Jefferies Sticks to Its Hold Rating for Cronos Group (CRON)
Jefferies Keeps Their Hold Rating on Cronos Group (CRON)
Jefferies Sticks to Its Hold Rating for Cronos Group (CRON)
B of A Securities Maintains Underperform on Cronos Group, Raises Price Target to $2
Cronos Group Analyst Ratings
Cronos Group Sell Rating Affirmed Amid Modest Sales Forecasts and Competitive Challenges
Cronos Group (CRON) Gets a Hold From Jefferies
Jefferies Keeps Their Hold Rating on Cronos Group (CRON)
Positive Market Outlook and Financial Health: A Buy Rating for Cronos Group
Sell Rating on Cronos Group: Uncertainty in Profitability and Regulatory Changes Overshadowing Robust Sales Performance
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Harmony Biosciences Holdings (HRMY) and Cronos Group (CRON)
Roth MKM Reiterates Buy on Cronos Group, Maintains C$5 Price Target
Cronos Group Analyst Ratings
Cronos Group (CRON) Receives a Buy From Roth MKM
Bank of America Securities Keeps Their Sell Rating on Cronos Group (CRON)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Acumen Pharmaceuticals (ABOS) and Cronos Group (CRON)
Analysis
Price Target
No Data
